...
首页> 外文期刊>Transplantation Proceedings >Twenty-seven consecutive intestinal and multivisceral transplants in adult patients: a 4-year clinical experience.
【24h】

Twenty-seven consecutive intestinal and multivisceral transplants in adult patients: a 4-year clinical experience.

机译:成年患者连续进行了27例肠和多脏器移植:4年的临床经验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Adult isolated intestinal and multivisceral transplantation is gaining acceptance as the standard treatment for patients with intestinal failure with life-threatening parenteral nutrition-related complications. We report our 4-year experience with intestinal and multivisceral transplantation. We performed 20 isolated small bowel and seven multivisceral ones, including three with liver. The underlying diseases were mainly short bowel syndrome due to intestinal infarction, chronic intestinal pseudo-obstruction, and Gardner syndrome. Indications for transplant were loss of central venous access in 14 patients, recurrent sepsis in eight patients, and major electrolyte and fluid imbalance in five patients. One-year patient actuarial survival rate was 94% for isolated intestinal transplants and 42% for multivisceral recipients (P = .003), while 1-year graft actuarial survival rate was 88.4% for isolated small bowel patients and 42.8% for multivisceral ones (P = .01). The death rate was 18.5%. Our graftectomyrate was 14.8%. Our immunosuppressive protocols were based on induction agents such as alemtuzumab, daclizumab, and antithymocyte globulins. The majority of our complications were bacterial infections, followed by rejections and relaparotomies; most rejection episodes were treated with steroid boluses and tapering. We believe that our results were due to optimal candidate and donor selection, short ischemia time, and use of induction therapy. Multivisceral transplantation is a more complex procedure with less frequent clinical indications than isolated small bowel transplant, but our data concerning multivisceral transplants include only a small number of patients and require further evaluation.
机译:成人隔离肠和多脏器移植已被接受为肠衰竭患者并危及生命的肠外营养相关并发症的标准治疗方法。我们报告了我们在肠道和多脏器移植方面的4年经验。我们进行了20例孤立的小肠和7例多脏器,其中3例带有肝脏。潜在疾病主要是由于肠梗塞,慢性肠假性梗阻和Gardner综合征引起的短肠综合征。移植的指征是14例患者失去中心静脉通路,8例患者复发败血症,以及5例患者严重的电解质和体液失衡。隔离肠移植的一年患者精算生存率为94%,多脏器接受者为42%(P = .003),而隔离小肠患者的一年移植精算生存率为88.4%,多脏器患者为42.8%( P = 0.01)。死亡率是18.5%。我们的移植物切除率为14.8%。我们的免疫抑制方案基于诱导剂,例如alemtuzumab,daclizumab和抗胸腺细胞球蛋白。我们的大多数并发症是细菌感染,随后是排斥反应和开腹手术。大多数排斥反应发作均采用类固醇大剂量治疗并逐渐缩小。我们认为,我们的结果是由于最佳的候选者和供体选择,较短的缺血时间和诱导疗法的使用。与单独的小肠移植相比,多器官移植是一种更复杂的过程,其临床指征较少,但是我们有关多器官移植的数据仅包括少数患者,需要进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号